Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.29 ▼ -0.45
(-5.15%)
MKT CAP: $8.79B • VOL: 8.96M
52W L $2 52W H $12
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$7
MEDIAN
$9
MEAN
$9
HIGH
$11
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IBRX TAPE
IBRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $10.03 | $9.53 | 2025-02-14 | $7.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $10.45 | $9.78 | 2025-02-06 | $7.79 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $9.45 | $9.12 | 2025-01-29 | $7.96 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $8.46 | — | 2025-01-17 | $8.12 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $7.30 | $7.88 | 2025-01-09 | $7.38 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $9.87 | $8.62 | 2024-12-18 | $7.21 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $8.04 | $8.37 | 2024-12-04 | $7.71 | -4.3% | 48% | C |